fenofibrate has been researched along with Cholangiitis, Sclerosing in 6 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adult patients with primary biliary cholangitis (PBC, n = 32) and primary sclerosing cholangitis (PSC, n = 23), who experienced an incomplete response while receiving ursodiol monotherapy (13-15 mg/kg/day), defined as serum alkaline phosphatase (ALP) ≥ 1." | 5.62 | Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. ( Assis, DN; Barbier, O; Boyer, JL; Gallucci, GM; Ghonem, NS; Hemme, C; Trottier, J, 2021) |
| "Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with no medical treatment proven to improve survival and postpone liver transplantation." | 3.11 | Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial. ( Ardakani, MJE; Gholami, S; Hassani, AH; Hatami, B; Mosala, M; Zali, MR, 2022) |
| "Adult patients with primary biliary cholangitis (PBC, n = 32) and primary sclerosing cholangitis (PSC, n = 23), who experienced an incomplete response while receiving ursodiol monotherapy (13-15 mg/kg/day), defined as serum alkaline phosphatase (ALP) ≥ 1." | 1.62 | Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. ( Assis, DN; Barbier, O; Boyer, JL; Gallucci, GM; Ghonem, NS; Hemme, C; Trottier, J, 2021) |
| "When fenofibrate was added to Ursodiol therapy there was a significant reduction and in some cases normalization of serum alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase abnormalities, as well as pro-inflammatory cytokines." | 1.56 | Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. ( Assis, DN; Auclair, AM; Boyer, JL; de la Rosa Rodriguez, R; Gallucci, GM; Ghonem, NS; Hemme, CL, 2020) |
| "In patients with primary sclerosing cholangitis (PSC), ursodeoxycholic acid (UDCA) treatment improves serum liver tests and surrogate markers of prognosis but has no proven effect on survival." | 1.48 | Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. ( Ben Belkacem, K; Chazouillères, O; Corpechot, C; Gaouar, F; Housset, C; Kemgang Fankem, AD; Lemoinne, S; Pares, A; Poupon, R; Reig, A, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gallucci, GM | 2 |
| Trottier, J | 1 |
| Hemme, C | 1 |
| Assis, DN | 2 |
| Boyer, JL | 2 |
| Barbier, O | 1 |
| Ghonem, NS | 2 |
| Hatami, B | 1 |
| Mosala, M | 1 |
| Hassani, AH | 1 |
| Ardakani, MJE | 1 |
| Gholami, S | 1 |
| Zali, MR | 1 |
| Auclair, AM | 1 |
| Hemme, CL | 1 |
| de la Rosa Rodriguez, R | 1 |
| Lemoinne, S | 1 |
| Pares, A | 1 |
| Reig, A | 1 |
| Ben Belkacem, K | 1 |
| Kemgang Fankem, AD | 1 |
| Gaouar, F | 1 |
| Poupon, R | 1 |
| Housset, C | 1 |
| Corpechot, C | 1 |
| Chazouillères, O | 1 |
| Abdalla, SM | 1 |
| Dejman, A | 1 |
| Clark, V | 1 |
| Levy, C | 1 |
| Bélénotti, P | 1 |
| Guervilly, C | 1 |
| Grandval, P | 1 |
| Benyamine, A | 1 |
| Ene, N | 1 |
| Serratrice, J | 1 |
| Petit, P | 1 |
| Laugier, R | 1 |
| Papazian, L | 1 |
| Weiller, PJ | 1 |
1 trial available for fenofibrate and Cholangiitis, Sclerosing
| Article | Year |
|---|---|
Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Alkaline Phosphatase; Bilirubin; Cholangitis, Sclerosing; Female; Fenofibrate; Humans; Liver | 2022 |
5 other studies available for fenofibrate and Cholangiitis, Sclerosing
| Article | Year |
|---|---|
Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.
Topics: Adult; Bile Acids and Salts; Cholangitis, Sclerosing; Cholestasis; Drug Therapy, Combination; Female | 2021 |
Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.
Topics: Adult; Aged; Bile Acids and Salts; Biomarkers; Cholangitis, Sclerosing; Cytokines; Drug Therapy, Com | 2020 |
Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Topics: Adult; Aged; Alkaline Phosphatase; Bezafibrate; Cholagogues and Choleretics; Cholangitis, Sclerosing | 2018 |
Use of Fenofibrate for patients with primary Sclerosing Cholangitis.
Topics: Cholangitis, Sclerosing; Fenofibrate; Fibric Acids; Humans; Ursodeoxycholic Acid | 2019 |
[Ischemic cholangitis in intensive care unit: favourable outcome with ursodesoxycholic acid and fenofibrate].
Topics: Cholagogues and Choleretics; Cholangitis, Sclerosing; Critical Care; Fenofibrate; Humans; Hypolipide | 2013 |